[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625947":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":24,"locations":29,"responsibleParty":52,"collaborators":54,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":24,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":24,"studyType":71,"phases":72,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":32,"whyStopped":24,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"PT. Prodia Stem Cell Indonesia","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"UC-MSC Secretome","EXPERIMENTAL","Umbilical Cord Mesenchymal Stem Cell-derived Secretome",[13],"Biological: Secretome",{"label":15,"type":10,"description":15,"interventionNames":16},"Platelet-Rich Plasma",[17],"Biological: Platelet-Rich Plasma (PRP) Injections",[19,25],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"BIOLOGICAL","Secretome","UC-MSC secretome was injected intradermally into the scalp at the alopecia site, with injections spaced 1 cm apart and administered every 2 weeks for 8 weeks",[9],null,{"type":20,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Platelet-Rich Plasma (PRP) Injections","The centrifuged plasma solution was injected intradermally into the scalp at the alopecia site, with 0.1 ml per injection point spaced 1 cm apart, administered every 2 weeks for 8 weeks",[15],[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Prof. dr. I.G.N.G. Ngoerah Central General Hospital","RECRUITING","Denpasar","Bali","80113","Indonesia","ID",{"type":39,"coordinates":40},"Point",[41,42],115.21667,-8.65,{"lat":42,"lon":41},[45,50],{"name":46,"role":47,"phone":48,"phoneExt":24,"email":49},"Dr. dr. I Gusti Nyoman Darmaputra, Sp.D.V.E., Subsp. O.B.K., FINS","CONTACT","+628124644451","darma@skincentrebali.com",{"name":46,"role":51,"phone":24,"phoneExt":24,"email":24},"PRINCIPAL_INVESTIGATOR",{"type":53,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[55],{"name":56,"class":57},"RS Prof. Dr. I.G.N.G Ngoerah","UNKNOWN","100625947","phase-1-secretome-vs-prp-injections-for-hair-density-and-growth-in-androgenetic-alopecia-patients-100625947",false,"NCT07429253","Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients","Comparative Effectiveness of Secretome Injection and Intradermal Platelet-Rich Plasma Injection on Hair Density and Terminal-to-Vellus Hair Ratio in Patients With Androgenetic Alopecia at Prof. Dr. I.G.N.G. Ngoerah General Hospital","Inclusion Criteria:\n\n* Male patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Hamilton-Norwood grades II to VI, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital.\n* Female patients with androgenetic alopecia, aged 25 to 59 years, with clinical presentation consistent with Ludwig grades I to III, seeking treatment at the Dermatology and Venereology Outpatient Clinic of Prof. Dr. I.G.N.G. Ngoerah General Hospital.\n* Female patients who are not currently pregnant or breastfeeding.\n* Patients who have discontinued anti-androgen medication and minoxidil for at least 1 month prior to the procedure.\n* Patients with no known allergies to secretome components and\u002For materials used in the platelet-rich plasma (PRP) preparation process.\n* Patients who are proficient in Indonesian and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Participants who are unable to speak or understand Indonesian and\u002For are unwilling to provide written informed consent.\n* Patients presenting with types of hair loss other than androgenetic alopecia.\n* Patients currently undergoing therapy with 5-alpha reductase inhibitors.\n* Patients who have received intradermal corticosteroid injections to the scalp within at least 6 months prior to the study.\n* Patients with active infections and\u002For active dermatitis on the scalp.\n* Patients with a known history of allergy to secretome components and\u002For materials used in the platelet-rich plasma (PRP) preparation process.\n* History of hypertrophic scarring or blood clotting (coagulation) disorders.\n* Patients unable to complete the research procedures in their entirety.","ALL","25 Years","59 Years",{"count":69,"type":70},40,"ESTIMATED","INTERVENTIONAL",[73,74],"PHASE1","PHASE2","This study aims to compare the effectiveness of secretome injection and intradermal platelet-rich plasma (PRP) injection on hair density and the terminal-to-vellus hair ratio in patients with androgenetic alopecia at Prof. Dr. I.G.N.G. Ngoerah General Hospital.",[77],"Androgenetic Alopecia",[21,15,77,79],"Trichoscopy","2026-02-17",{"date":82,"type":83},"2026-02-24","ACTUAL",{"date":85,"type":83},"2026-01-09",{"date":87,"type":70},"2026-09-30",{"name":5,"class":6},1]